Route of administration of magnesium replacement in the IC

Phase 4

Recruiting

• Conditions: Hypomagnesemia; Critical Illness; Metabolic and Endocrine - Other metabolic disorders; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12623000248662
• Lead Sponsor: Royal Melbourne Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-08
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

All adult patients admitted to the RMH ICU who require magnesium replacement with serum magnesium level of <0.7 mmol/

Exclusion Criteria

- Serum magnesium concentration <0.7 mmol/l and new cardiac arrhythmia; or serum magnesium concentration less than or equal to 0.35 mmol/l (ie., severe hypomagnesemia)
- Either enteral or parenteral replacement is not possible (ie., no enteric feeding tube, intolerance of enteral feeding with gastric aspiration >300ml or no intravenous line)
- Treating clinician believes that either enteral or parenteral magnesium is indicated for this patient
-Patient's currently having enteral magnesium replacement order

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure is serum magnesium level measured before magnesium replacement and 24 hours after replacement.[ Prior to magnesium replacement and 24 hours after replacement.]